GleamWall
中文EN

MTNB Matinas BioPharma Holdings, Inc.

Pharmaceutical Preparations · NYSE · SEC CIK 1582554 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY58.9%
TTM EPS YoY114.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-147.5%
ROA-98.4%
ROIC (approx.)-535.3%
Asset turnover—

Leverage & solvency

Liabilities / assets33.1%
Debt / equity0.00x
Current ratio1.78x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.95x
Accruals ratio-5.2%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$85,000$11.43M
SG&A expense$6.88M$8.73M
Operating income-$6.96M-$24.59M
Pretax income-$10.35M-$24.33M
Income tax—-$80,000
Net income-$10.35M-$24.25M
EBITDA-$6.93M-$24.23M
EPS (basic)-2.00-4.98
EPS (diluted)-2.00-4.98
Weighted avg. shares (diluted)5.47M4.87M
Balance sheet
Cash & equivalents$4.00M$7.28M
Current assets$4.08M$8.03M
PP&E, net$138,000$468,000
Intangibles$2.26M$2.26M
Total assets$7.21M$12.64M
Current liabilities$1.46M$2.67M
Total liabilities$2.38M$5.05M
Shareholders' equity$4.83M$7.59M
Shares outstanding427,0795.09M
Cash flow statement
Operating cash flow-$7.01M-$15.88M
Investing cash flow$335,000$9.21M
Financing cash flow$3.39M$9.17M
Depreciation & amortization$32,000$365,000
Stock-based compensation$1.02M$3.19M

Free plan shows the latest 2 periods; Pro shows all 13 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.